Infinium PharmachemNSE:INFINIUM +2.15%86 EBITDA Margin % is 11.61% as of Mar. 2026, which is 2% below its 10-year median of 11.90. GuruFocus rates NSE:INFINIUM with a GF Score™ of 86/100 and a GF Value™ of ₹303.68 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 1,579 Chemicals companies, Infinium Pharmachem ranks better than 61.11% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Infinium Pharmachem EBITDA Margin % Related Terms
Infinium Pharmachem EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Infinium Pharmachem's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Chemicals subindustry, Infinium Pharmachem's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Infinium Pharmachem EBITDA Margin % vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Infinium Pharmachem's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Infinium Pharmachem's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Infinium Pharmachem (NSE:INFINIUM) has a EBITDA Margin % of 11.61% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Infinium Pharmachem and its competitors. This is near median its historical median of 11.90. Over the past decade, Infinium Pharmachem's EBITDA Margin % has ranged from 7.14 to 14.96. According to the industry distribution chart, Infinium Pharmachem ranks #614 out of 1579 companies in the Chemicals industry, placing it in the top 38.9%.
Is Infinium Pharmachem's EBITDA Margin % too high?
Infinium Pharmachem's current EBITDA Margin % of 11.61% is near median its 10-year median of 11.90. Over the past 10 years, this metric has ranged from a low of 7.14 to a high of 14.96. The Chemicals industry median EBITDA Margin % is 9.63. Infinium Pharmachem's value of 11.61% is 20.6% above this industry median. Based on the distribution chart, Infinium Pharmachem ranks #614 out of 1579 companies in the Chemicals industry, which is above the industry midpoint. Overall, Infinium Pharmachem has a GF Score™ of 86/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Infinium Pharmachem's EBITDA Margin % compare to DOW?
According to the Chemicals industry distribution chart, Infinium Pharmachem ranks #614 out of 1579 companies for EBITDA Margin %. This puts Infinium Pharmachem in the upper half of its industry. The industry median EBITDA Margin % is 9.63. Infinium Pharmachem's value of 11.61% is 20.6% above this benchmark. Historically, Infinium Pharmachem's own EBITDA Margin % has ranged from 7.14 to 14.96 over the past decade. While the company's 10-year median is 11.90 vs. the industry median of 9.63, Infinium Pharmachem has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Chemicals company?
The median EBITDA Margin % among Chemicals companies is 9.63, based on 1,579 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Infinium Pharmachem's current EBITDA Margin % of 11.61% is 20.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Infinium Pharmachem and its competitors. For the Chemicals industry, the median EBITDA Margin % is 9.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Infinium Pharmachem's current EBITDA Margin % is 11.61%, which is near median its own 10-year median of 11.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Infinium Pharmachem stock overvalued right now?
Based on GuruFocus' analysis, Infinium Pharmachem (NSE:INFINIUM) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹303.68, compared to a current price of ₹204.30 — trading 32.7% below its estimated fair value. The current EBITDA Margin % is 11.61%, which is near median its 10-year median of 11.90 and 20.6% above the Chemicals industry median of 9.63. Infinium Pharmachem's overall GF Score™ is 86/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Infinium Pharmachem (NSE:INFINIUM), the current EBITDA Margin % is 11.61% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Infinium Pharmachem (NSE:INFINIUM) Overvalued in 2026?
Based on GuruFocus' analysis, Infinium Pharmachem stock appears to be undervalued.
The current stock price of ₹204.30 is trading 32.7% below its estimated GF Value™ of ₹303.68.
GuruFocus considers Infinium Pharmachem to be Significantly Undervalued.
Key valuation signals for NSE:INFINIUM:
EBITDA Margin %: 11.61% (near median its 10-year median of 11.90)
GF Value™: ₹303.68 vs. price of ₹204.30 (32.7% below fair value)
Industry Position: 20.6% above the Chemicals median (#614 of 1579)
No single metric tells the full story. See the NSE:INFINIUM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Infinium Pharmachem Ltd is engaged in the business of manufacturing and supplying Iodine, Iodine Derivatives and Active Pharmaceutical Ingredients (APIs). It provides fully integrated customized services from R & D to Commercial scale manufacturing and packaging for its products to the Pharmaceutical, Agrochemical, Nutraceutical, Speciality Chemicals and various other chemicals Industries.
86GF Score
Get the complete analysis for NSE:INFINIUM
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INFINIUM has been successfully added to your 
